Antibody-Drug Conjugates

Kumar, Amit; White, Jason B.; Christie, R. James; Dimasi, Nazzareno; Gao, Changshou

doi:10.1016/bs.armc.2017.08.002

Cited by 21 publications

(20 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is attributed to the replacement of the N -hydroxysuccinimide (NHS) group in PBASE with the amine group in the antibody. Because the NHS ester, which consists of two N–C=O centers, is an electron-withdrawing group, 53 the removal of the NHS group makes graphene less p-doped, which is represented by a decrease in the 2D band peak wavenumber.…”

Section: Resultsmentioning

confidence: 99%

COVID-19 Spike Protein Induced Phononic Modification in Antibody-Coupled Graphene for Viral Detection Application

Nguyen

Kim

Lindemann³

et al. 2021

ACS Nano

View full text Add to dashboard Cite

With an incubation time of about 5 days, early diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to control the spread of the coronavirus disease 2019 (COVID-19) that killed more than 3 million people in its first 1.5 years. Here, we report on the modification of the dopant density and the phononic energy of antibody-coupled graphene when it interfaces with SARS-CoV-2 spike protein. This graphene chemeo-phononic system was able to detect SARS-CoV-2 spike protein at the limit of detection of ∼3.75 and ∼1 fg/mL in artificial saliva and phosphate-buffered saline, respectively. It also exhibited selectivity over proteins in saliva and MERS-CoV spike protein. Since the change in graphene phononics is monitored instead of the phononic signature of the analyte, this optical platform can be replicated for other COVID variants and specific-binding-based biodetection applications.

show abstract

Section: Resultsmentioning

confidence: 99%

COVID-19 Spike Protein Induced Phononic Modification in Antibody-Coupled Graphene for Viral Detection Application

Nguyen

Kim

Lindemann³

et al. 2021

ACS Nano

View full text Add to dashboard Cite

show abstract

“…Treatments involving folate-targeted approaches were extensively studied in the context of different therapeutic cargos, including chemotherapeutic agents, imaging agents, oligonucleotides, and DNA molecules (Kumar et al 2019). One of the widely used chemotherapeutic agents is doxorubicin (DOX), a topoisomerase inhibitor whose interaction with DNA leads to the suppression of cancer cell growth (Kumar et al 2017). DOX is useful for treating various types of cancer, including lung (Hong et al 2019), breast (Lovitt et al 2018), colon (Lin et al 2018), and hematologic cancers (Au et al 2019).…”

Section: Introductionmentioning

confidence: 99%

Quantum dots as targeted doxorubicin drug delivery nanosystems in human lung cancer cells

et al. 2021

View full text Add to dashboard Cite

Background Lung cancer is one of the most frequently diagnosed cancers all over the world and is also one of the leading causes of cancer-related mortality. The main treatment option for small cell lung cancer, conventional chemotherapy, is characterized by a lack of specificity, resulting in severe adverse effects. Therefore, this study aimed at developing a new targeted drug delivery (TDD) system based on Ag–In–Zn–S quantum dots (QDs). For this purpose, the QD nanocrystals were modified with 11-mercaptoundecanoic acid (MUA), L-cysteine, and lipoic acid decorated with folic acid (FA) and used as a novel TDD system for targeting doxorubicin (DOX) to folate receptors (FARs) on adenocarcinomic human alveolar basal epithelial cells (A549). NIH/3T3 cells were used as FAR-negative controls. Comprehensive physicochemical, cytotoxicity, and genotoxicity studies were performed to characterize the developed novel TDDs. Results Fourier transformation infrared spectroscopy, dynamic light scattering, and fluorescence quenching confirmed the successful attachment of FA to the QD nanocrystals and of DOX to the QD–FA nanocarriers. UV–Vis analysis helped in determining the amount of FA and DOX covalently anchored to the surface of the QD nanocrystals. Biological screening revealed that the QD–FA–DOX nanoconjugates had higher cytotoxicity in comparison to the other forms of synthesized QD samples, suggesting the cytotoxic effect of DOX liberated from the QD constructs. Contrary to the QD–MUA–FA–DOX nanoconjugates which occurred to be the most cytotoxic against A549 cells among others, no such effect was observed for NIH/3T3 cells, confirming FARs as molecular targets. In vitro scratch assay also revealed significant inhibition of A549 cell migration after treatment with QD–MUA–FA–DOX. The performed studies evidenced that at IC50 all the nanoconjugates induced significantly more DNA breaks than that observed in nontreated cells. Overall, the QD–MUA–FA–DOX nanoconjugates showed the greatest cytotoxicity and genotoxicity, while significantly inhibiting the migratory potential of A549 cells. Conclusion QD–MUA–FA–DOX nanoconjugates can thus be considered as a potential drug delivery system for the effective treatment of adenocarcinomic human alveolar basal epithelial cells.

show abstract

“…Due to the steric bulk of the payload, the PABC spacer also facilitates enzyme access allowing the vc group to be recognized by cathepsin B [ 20 , 60 , 61 ]. Cathepsin B is a cysteine protease which presents almost exclusively in the lysosomal compartment in healthy mammals, and is overexpressed in multiple cancer types [ 62 , 63 ]. It is responsible for cleaving the citrulline-PABC amide bond.…”

Section: Fda Approved Adcsmentioning

confidence: 99%

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy

et al. 2021

View full text Add to dashboard Cite

The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has resulted in a significant market ‘boom’, garnering worldwide attention. Despite ADCs presenting huge challenges to researchers, particularly regarding the identification of a suitable combination of antibody, linker, and payload, as of September 2021, 11 ADCs have been granted FDA approval, with eight of these approved since 2017 alone. Optimism for this therapeutic approach is clear, despite the COVID-19 pandemic, 2020 was a landmark year for deals and partnerships in the ADC arena, suggesting that there remains significant interest from Big Pharma. Herein we review the enthusiasm for ADCs by focusing on the features of those approved by the FDA, and offer some thoughts as to where the field is headed.

show abstract

Antibody-Drug Conjugates

Cited by 21 publications

References 127 publications

COVID-19 Spike Protein Induced Phononic Modification in Antibody-Coupled Graphene for Viral Detection Application

COVID-19 Spike Protein Induced Phononic Modification in Antibody-Coupled Graphene for Viral Detection Application

Quantum dots as targeted doxorubicin drug delivery nanosystems in human lung cancer cells

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy

Contact Info

Product

Resources

About